Thr177

Site Information
VAGQLTDtMAkRNtV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 450049

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 3 , 4 , 5 , 6 , 7 ) , phospho-antibody ( 2 ) , western blotting ( 2 )
Disease tissue studied:	leukemia ( 2 ) , T cell leukemia ( 2 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:	HCT116 (intestinal) ( 7 ) , HeLa (cervical) ( 6 ) , Jurkat (T lymphocyte) ( 2 , 5 ) , K562 (erythroid) ( 4 ) , MDA-MB-435S (breast cell) ( 7 ) , MV4-11 (macrophage) ( 7 ) , WM239A (melanocyte) ( 3 )

Upstream Regulation
Treatments:	pictilisib ( 2 ) , SCH772984 ( 2 ) , Y27632 ( 6 )

References
1	Turunen SP, et al. (2019) FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis. Cell Death Differ 30903103 Curated Info
2	Nováková J, Talacko P, Novák P, Vališ K (2019) The MEK-ERK-MST1 Axis Potentiates the Activation of the Extrinsic Apoptotic Pathway during GDC-0941 Treatment in Jurkat T Cells. Cells 8 30795621 Curated Info
3	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
4	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
5	Mulhern D (2012) CST Curation Set: 13829; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Curated Info
6	Nishioka T, Nakayama M, Amano M, Kaibuchi K (2012) Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3ζ affinity chromatography. Cell Struct Funct 37, 39-48 22251793 Curated Info
7	Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64 19369195 Curated Info